We have completed a review of the drugs listed in the contraceptive/HRT class of the checker to ensure that the information provided is consistent, clinically useful and up to date.
As a result of this review, HRT summaries were revised to include mention of the estrogen component (to be consistent with combined oral contraceptives) and, where required, interactions were recoded from green to amber to take into consideration the interaction with coadministered estrogens.
Several new drugs were added to the class to ensure that the drug list reflects global availability and use. The new drugs that are now included in the checker are:- Bazedoxifene
- Conjugated estrogens
- Drospirenone (POP)
- Norgestimate (HRT)
- Progesterone (HRT)
- Tibolone (HRT)
In addition, medroxyprogesterone (oral) has been split into two indications – medroxyprogesterone used for HRT (in the Contraceptive/HRT class) and medroxyprogesterone used at low doses for dysfunctional uterine bleeding, secondary amenorrhoea and mild/moderate endometriosis or at high doses for hormone dependant neoplasms (in the “Other” class).
Finally, notes have been included in the summaries for ethinylestradiol and conjugated estrogens mentioning that their use in gender hormone therapy is not recommended.
Updated PDF interaction charts are available in the Prescribing Resources section of the website.
